References
- Alvarez A, Aleixandre M, Linares C, et al. (2014). Apathy and APOE4 are associated with reduced BDNF levels in Alzheimer's disease. J Alzheimers Dis [Epub ahead of print]
- Badia MC, Lloret A, Giraldo E, et al. (2013). Lymphocytes from young healthy persons carrying the ApoE4 allele overexpress stress-related proteins involved in the pathophysiology of Alzheimer's disease. J Alzheimers Dis 33:77–83
- Blennow K, Hampel H, Weiner M, et al. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131–44
- De La Monte SM, Wands JR. (2002). The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. Front Biosci 7:d989–96
- Desai AK, Grossberg GT. (2005). Diagnosis and treatment of Alzheimer's disease. Neurology 64:S34–9
- Diniz BS, Reynolds CF III, Begley A, et al. (2014). Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: alongitudinal study. J Psychiatr Res 49:96–101
- Forlenza OV, Diniz BS, Teixeira AL, et al. (2010). Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry 11:774–80
- Hampel H, Frank R, Broich K, et al. (2010). Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9:560–74
- Hixson JE, Vernier DT. (1990). Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–8
- Humpel C. (2011). Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 29:26–32
- Lin AL, Laird AR, Fox PT, et al. (2012). Multimodal MRI neuroimaging biomarkers for cognitive normal adults, amnestic mild cognitive impairment, and Alzheimer's disease. Neurol Res Int 2012:907409
- Liu CC, Kanekiyo T, Xu H, et al. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–8
- McKhann G, Drachman D, Folstein M, et al. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–44
- Pa J, Boxer A, Chao LL, et al. (2009). Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol 65:414–23
- Petersen RC. (2004). Mild cognitive impairment as a diagnostic entity. J Int Med 256:183–94
- Petersen RC, Smith GE, Waring SC, et al. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–8
- Petersen RC, Thomas RG, Grundman M, et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379–88
- Saunders AM, Hulette O, Welsh-Bohmer KA, et al. (1996). Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 348:90–3
- Tan J, Town T, Abdullah L, et al. (2002). CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. J Neuroimmunol 132:164–72
- Vemuri P, Wiste HJ, Weigand SD, et al. (2010). Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67:308–16
- Youn YC, Park KW, Han SH, et al. (2011). Urine neural thread protein measurements in Alzheimer disease. J Am Med Dir Assoc 12:372–6